Cardinal Health, Inc. (NYSE:CAH – Get Free Report) CEO Deborah Weitzman sold 7,354 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the completion of the transaction, the chief executive officer directly owned 77,901 shares of the company’s stock, valued at $18,341,790.45. The trade was a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Cardinal Health Stock Performance
NYSE:CAH opened at $228.95 on Friday. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30. The firm has a market cap of $53.25 billion, a price-to-earnings ratio of 31.67, a PEG ratio of 1.26 and a beta of 0.49. The business’s fifty day moving average is $231.91 and its 200 day moving average is $217.78.
Cardinal Health (NYSE:CAH – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Equities analysts predict that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.
Cardinal Health Announces Dividend
Key Cardinal Health News
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
- Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
- Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
- Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
- Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis
Institutional Investors Weigh In On Cardinal Health
Several hedge funds have recently bought and sold shares of the stock. Investors Research Corp bought a new position in shares of Cardinal Health in the 2nd quarter worth $29,000. University of Texas Texas AM Investment Management Co. purchased a new position in Cardinal Health in the fourth quarter worth $26,000. Allied Private Wealth LLC bought a new position in Cardinal Health in the second quarter valued at $30,000. Bank of Jackson Hole Trust bought a new position in Cardinal Health in the fourth quarter valued at $27,000. Finally, Indiana Trust & Investment Management Co purchased a new stake in Cardinal Health during the first quarter valued at about $29,000. 87.17% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
CAH has been the topic of a number of analyst reports. Evercore reaffirmed an “outperform” rating and set a $270.00 target price on shares of Cardinal Health in a report on Wednesday, August 12th. Robert W. Baird raised their price target on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Zacks Research cut shares of Cardinal Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 12th. William Blair assumed coverage on Cardinal Health in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company lifted their price objective on Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Cardinal Health has a consensus rating of “Moderate Buy” and a consensus price target of $266.56.
View Our Latest Report on Cardinal Health
About Cardinal Health
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
Featured Stories
- Five stocks we like better than Cardinal Health
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.
